In breast cancer cells the membrane type III TGFβ coreceptor (TβRIII) is highly expressed, and can inhibit TGFβ or BMP signals via at least two different modes: (1) by shedding to form a soluble sTβRIII that can sequester the BMP ligand and prevent subsequent membrane binding and SMAD1/5/8 activation [144]; (2) by complexing with TβRI or TβRII and competing with TβRI/TβRII complex formation [145]. Here, SMAD1 is linked to breast carcinoma.